Senvest Management LLC Has $190.38 Million Stock Position in Illumina, Inc. $ILMN

Senvest Management LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 10.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,544,567 shares of the life sciences company’s stock after buying an additional 142,686 shares during the quarter. Illumina makes up about 6.3% of Senvest Management LLC’s investment portfolio, making the stock its 3rd largest position. Senvest Management LLC’s holdings in Illumina were worth $190,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of ILMN. WCM Investment Management LLC raised its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Morgan Stanley lifted its holdings in Illumina by 66.0% during the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after purchasing an additional 1,005,474 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. acquired a new position in Illumina in the first quarter valued at about $106,462,000. 89.42% of the stock is currently owned by institutional investors.

Insider Transactions at Illumina

In related news, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares in the company, valued at $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. Corporate insiders own 2.90% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Neutral Sentiment: Illumina was highlighted in a batch of valuation and relative-performance articles comparing it with peers such as Exelixis and Celldex Therapeutics, which may be keeping attention on whether ILMN looks cheap or expensive versus other healthcare names. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Analyst sentiment remained middling, with Illumina reported as having an average “Hold” recommendation, suggesting Wall Street is not seeing an immediate reason to aggressively buy or sell the shares. Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Coverage around Illumina’s role in the Billion Cell Atlas alliance and broader genomics/CRISPR collaboration was noted in commentary on AstraZeneca, but this appears more like a long-term strategic backdrop than a near-term stock mover. AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares outstanding for short positions, so there is no clear evidence here of a new bearish squeeze or panic selling signal.

Illumina Trading Down 1.4%

Shares of NASDAQ ILMN opened at $194.09 on Friday. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $199.14. The company has a 50-day moving average of $171.24 and a two-hundred day moving average of $145.40. The company has a market cap of $29.37 billion, a PE ratio of 35.29, a P/E/G ratio of 2.91 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business posted $0.97 earnings per share. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ILMN. Canaccord Genuity Group raised their price objective on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Sanford C. Bernstein initiated coverage on Illumina in a report on Friday, June 26th. They issued a “market perform” rating and a $185.00 target price on the stock. Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Finally, Piper Sandler lifted their price objective on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Nine analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Illumina has a consensus rating of “Hold” and a consensus target price of $156.88.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.